Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 1
2011 1
2012 2
2013 1
2014 1
2015 2
2017 2
2018 2
2019 3
2020 1
2021 1
Text availability
Article attribute
Article type
Publication date

Search Results

14 results
Results by year
Filters applied: . Clear all
Page 1
Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis: results of an international phase 2 study.
Donadieu J, Bernard F, van Noesel M, Barkaoui M, Bardet O, Mura R, Arico M, Piguet C, Gandemer V, Armari Alla C, Clausen N, Jeziorski E, Lambilliote A, Weitzman S, Henter JI, Van Den Bos C; Salvage Group of the Histiocyte Society. Donadieu J, et al. Among authors: van noesel m. Blood. 2015 Sep 17;126(12):1415-23. doi: 10.1182/blood-2015-03-635151. Epub 2015 Jul 20. Blood. 2015. PMID: 26194764 Free PMC article. Clinical Trial.
The protocol, comprising at least two 5-day courses of Ara-C (1 g/m(2) per day) plus cladribine (9 mg/m(2) per day) followed by maintenance therapy, was administered to 27 patients (median age at diagnosis, 0.7 years; median follow-up, 5.3 years). ...
The protocol, comprising at least two 5-day courses of Ara-C (1 g/m(2) per day) plus cladribine (9 mg/m(2) per day) followed b …
Neuroblastoma between 1990 and 2014 in the Netherlands: Increased incidence and improved survival of high-risk neuroblastoma.
Tas ML, Reedijk AMJ, Karim-Kos HE, Kremer LCM, van de Ven CP, Dierselhuis MP, van Eijkelenburg NKA, van Grotel M, Kraal KCJM, Peek AML, Coebergh JWW, Janssens GOR, de Keizer B, de Krijger RR, Pieters R, Tytgat GAM, van Noesel MM. Tas ML, et al. Among authors: van noesel mm. Eur J Cancer. 2020 Jan;124:47-55. doi: 10.1016/j.ejca.2019.09.025. Epub 2019 Nov 11. Eur J Cancer. 2020. PMID: 31726247 Free article.
Health-Related Quality of Life of Adolescents with Cancer During the First Year of Treatment.
Bult MK, van Bindsbergen KLA, Schepers SA, de Ridder-Sluiter HG, Verhaak CM, van Litsenburg RRL, Merks JHM, van Noesel MM, Grootenhuis MA. Bult MK, et al. Among authors: van noesel mm. J Adolesc Young Adult Oncol. 2019 Oct;8(5):616-622. doi: 10.1089/jayao.2019.0017. Epub 2019 Jul 3. J Adolesc Young Adult Oncol. 2019. PMID: 31268387
Cancer-specific item scores were dichotomized and percentages were calculated to determine the proportion of adolescents reporting presence or absence of problems. Results: A total of 73 (mean [M](age) = 14.71, standard deviation [SD] = 1.85) adolescents with cancer (M
Cancer-specific item scores were dichotomized and percentages were calculated to determine the proportion of adolescents reporting presence …
Peripheral Stem Cell Apheresis is Feasible Post 131Iodine-Metaiodobenzylguanidine-Therapy in High-Risk Neuroblastoma, but Results in Delayed Platelet Reconstitution.
Kraal KCJM, Timmerman I, Kansen HM, van den Bos C, Zsiros J, van den Berg H, Somers S, Braakman E, Peek AML, van Noesel MM, van der Schoot CE, Fiocco M, Caron HN, Voermans C, Tytgat GAM. Kraal KCJM, et al. Among authors: van noesel mm. Clin Cancer Res. 2019 Feb 1;25(3):1012-1021. doi: 10.1158/1078-0432.CCR-18-1904. Epub 2018 Oct 12. Clin Cancer Res. 2019. PMID: 30314967 Free article.
Upfront treatment of high-risk neuroblastoma with a combination of 131I-MIBG and topotecan.
Kraal KC, Tytgat GA, van Eck-Smit BL, Kam B, Caron HN, van Noesel M. Kraal KC, et al. Among authors: van noesel m. Pediatr Blood Cancer. 2015 Nov;62(11):1886-91. doi: 10.1002/pbc.25580. Epub 2015 May 15. Pediatr Blood Cancer. 2015. PMID: 25981988 Clinical Trial.
METHODS: In a prospective, window phase II study, patients with newly diagnosed high-risk neuroblastoma were treated at diagnosis with two courses of (131) I-MIBG directly followed by topotecan (0.7 mg/m(2) for 5 days). After these two courses, standard induction treatment …
METHODS: In a prospective, window phase II study, patients with newly diagnosed high-risk neuroblastoma were treated at diagnosis with two c …
3-Methoxytyramine: An independent prognostic biomarker that associates with high-risk disease and poor clinical outcome in neuroblastoma patients.
Verly IRN, van Kuilenburg ABP, Abeling NGGM, Goorden SMI, Fiocco M, Vaz FM, van Noesel MM, Zwaan CM, Kaspers GJL, Merks JHM, Caron HN, Tytgat GAM. Verly IRN, et al. Among authors: van noesel mm. Eur J Cancer. 2018 Feb;90:102-110. doi: 10.1016/j.ejca.2017.11.025. Epub 2017 Dec 21. Eur J Cancer. 2018. PMID: 29274926
Catecholamines profiles at diagnosis: Increased diagnostic sensitivity and correlation with biological and clinical features in neuroblastoma patients.
Verly IR, van Kuilenburg AB, Abeling NG, Goorden SM, Fiocco M, Vaz FM, van Noesel MM, Zwaan CM, Kaspers GL, Merks JH, Caron HN, Tytgat GA. Verly IR, et al. Among authors: van noesel mm. Eur J Cancer. 2017 Feb;72:235-243. doi: 10.1016/j.ejca.2016.12.002. Epub 2017 Jan 4. Eur J Cancer. 2017. PMID: 28061374
Clustering of hypermethylated genes in neuroblastoma.
van Noesel MM, van Bezouw S, Voûte PA, Herman JG, Pieters R, Versteeg R. van Noesel MM, et al. Genes Chromosomes Cancer. 2003 Nov;38(3):226-33. doi: 10.1002/gcc.10278. Genes Chromosomes Cancer. 2003. PMID: 14506696
14 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page